Angola

Angola has basic but gradually developing dementia-care capacity. Major referral hospitals in Luanda provide neurology, imaging, clinical psychology, nuclear medicine and related services relevant to dementia diagnosis. The Cardeal Dom Alexandre do Nascimento hospital is particularly important because its formal structure includes neurology, imaging, nuclear medicine and advanced laboratory services. The Ministry of Health is also beginning to incorporate Alzheimer’s disease explicitly into neuroscience capacity-building, and specialist training in neurology and geriatrics is expanding.

The principal weaknesses are the absence of a standardized national dementia pathway, no dedicated dementia strategy, no national registry, limited access to advanced biomarkers, major geographic inequalities and weak dementia-specific caregiver support. WHO continues to identify substantial health-financing and access problems, including high out-of-pocket costs. Family members therefore remain central to long-term dementia care.

Overall
AD Rating
Diagnostic Pathway
Dementia can be investigated through general medicine, neurology, psychiatry and geriatric services, particularly at major hospitals in Luanda, with CT/MRI and laboratory testing available at higher-level facilities. However, there is no standardized nationwide dementia pathway or Memory Clinic network, and advanced biomarkers/genetic testing are not routinely available.
Specialized Care
Basic medical and supportive dementia care is available, especially in urban specialist hospitals, but access is geographically and financially uneven. Angola has a national Essential Medicines List, but the evidence does not support treating the full range of standard Alzheimer medicines as consistently accessible nationwide.
Caregiver Support
Dementia care remains predominantly family-based. Broader older-person and social-support programmes exist, but there is no comprehensive national dementia-specific caregiver system comparable to those providing structured respite, training, counselling and dementia helplines in stronger systems.
National Policies
Angola has no dedicated national dementia strategy. Dementia can fall within broader neurological, mental-health, ageing and NCD policies. The 2024–2027 national NCD plan explicitly includes mental and neurological disorders, representing some policy progress, but it is not dementia-specific. WHO also reports continuing work on updating Angola's broader national health policies and development plan.
Access to ATT-s
No therapies approved.
Organizations are listed for informational purposes based on publicly available sources. Inclusion does not necessarily indicate affiliation with or endorsement by Alzheimer’s Disease International (ADI).

Highlights

Health system
Non-universal and mixed funds and provisions.
ADI member association(s)
National dementia plan
Dementia plan funding
No plan
Dementia prevalence rate
161
Dementia incidence rate
28
*per 100k Population
Prevalence Rate (per 100,000): 
This measures the total number of existing cases (both old and new) in a population at a specific point in time, divided by the total population and multiplied by 100,000. It tells you the overall "burden" or how widespread a condition is at that moment.
Incidence Rate (per 100,000): 
This measures the number of new cases that develop in a population over a specific period (usually one year), divided by the population at risk and multiplied by 100,000. This tells you the "speed" or risk of contracting the condition.

Population

40,349,878

Median age

16.7

Health expenditure (% of GDP)

2.55

Diagnosis

Angola’s dementia diagnostic system remains under development, with no nationally standardised pathway or mandated cognitive screening tool. Assessment may combine clinical and functional evaluation, MMSE or MoCA, laboratory testing, neurology or psychiatry referral, and CT/MRI where accessible. The Cardeal Dom Alexandre do Nascimento hospital has relatively broad neurological and diagnostic capacity, including neurology, imaging, nuclear medicine, psychology, and laboratory services, but advanced services remain concentrated in major urban and referral centres. There is no evidence that APOE or familial Alzheimer’s genetic testing is routine, and APP, PSEN1, or PSEN2 testing would likely require research, private specialist arrangements, or external referral. Waiting times are not nationally reported, while geographical disparities and workforce limitations can delay assessment outside Luanda. Although some public services are subsidised, patients may incur substantial costs for private consultations, imaging, medicines, and transportation. Capacity is gradually expanding through specialist medical training and a 2025 national neuroscience initiative identifying Alzheimer’s disease among conditions requiring strengthened technical expertise.

Diagnosis pathway

Angola has no nationally standardised dementia diagnostic pathway. Assessment may include clinical, cognitive, functional, and laboratory evaluation, followed by neurology or psychiatry referral and CT or MRI where accessible. Specialist and diagnostic capacity is concentrated particularly in Luanda, although recent neuroscience initiatives aim to strengthen national expertise in Alzheimer’s disease and other neurological conditions.

Angola does not appear to have a nationally standardized dementia diagnostic pathway. Where specialist services are available, patients may be referred to neurology or psychiatry for further evaluation, with CT or MRI performed when necessary and accessible, particularly at larger referral hospitals. Access to more complex neurological assessment and diagnostic technology remains concentrated in major urban centres, especially Luanda. The practical pathway can therefore be summarized as initial medical assessment followed by cognitive and functional evaluation, laboratory testing, specialist referral and neuroimaging where available, leading to diagnosis, symptomatic treatment and family or social support.

The Complexo Hospitalar de Doenças Cardiopulmonares Cardeal Dom Alexandre do Nascimento formally includes neurology, neurosurgery, internal medicine, diagnostic imaging, nuclear medicine, clinical psychology and laboratory diagnostics. The Ministry of Health has also started explicitly strengthening dementia-related neurological capacity. In July 2025, a national neuroscience initiative identified Alzheimer’s disease, Parkinson’s disease, stroke, epilepsy and neuropathies among the neurological conditions requiring expanded technical capacity.

Wait times

Angola has no national dementia-specific waiting-time indicators. Workforce shortages and geographically concentrated specialist and imaging services can delay assessment, especially outside Luanda, while faster private-sector access may increase household costs.

Angola does not publish national dementia-specific waiting-time data. Waiting times are likely to vary substantially according to geography, specialist availability and the patient’s ability to pay for private care. WHO continues to identify health-worker shortages, uneven access and limited system capacity as major structural challenges. Patients living outside Luanda or other major urban centres may need to travel considerable distances for neurology, CT, MRI or specialist assessment. Private-sector services may sometimes provide faster access, but this shifts a larger share of the financial burden onto households.

Diagnosis cost

Partially covered

Although Angola subsidises some public diagnostic services, dementia assessment can involve substantial out-of-pocket costs. Patients may pay for specialist consultations, laboratory tests, CT or MRI, medicines, and transport when public provision is unavailable.

Public-sector consultations and investigations can be subsidized or provided through state hospitals, but Angola does not provide comprehensive financial protection across the entire diagnostic pathway. WHO’s health-financing review identifies high out-of-pocket expenditure and inadequate financial protection as persistent problems in Angola. Patients may therefore pay for private specialist consultations, laboratory tests, imaging, medicines and transportation when public-sector services are unavailable or geographically distant. For dementia, this is particularly important because a complete diagnosis may require several consultations plus CT/MRI and specialist review.

Cognitive tests

Available

There is no evidence of a nationally mandated dementia cognitive screening instrument. Neurologists, psychiatrists and trained physicians can use conventional tools such as the MMSE, MoCA or similar bedside cognitive assessments, but no evidence was found of universal standardized use across the national public system. Formal neuropsychological assessment is likely to be concentrated in larger hospitals and specialist centres. Angola is expanding specialist medical training. The 2025 medical internship framework formally includes specialties such as Neurology, Geriatrics and Psychiatry, which may gradually strengthen the country’s capacity to assess cognitive disorders.

Imaging tests

Used in specific cases

CT and MRI are available in Angola, particularly at tertiary hospitals and private diagnostic centres. The Cardeal Dom Alexandre do Nascimento hospital includes both an Imaging Service and a Nuclear Medicine Service within its formal structure. The same hospital has undergone major modernization and is equipped for high-complexity neurological and neurosurgical care, serving referred patients from several provinces. This means structural neuroimaging needed for dementia differential diagnosis is technically available. However, CT and MRI should not be described as universally or easily accessible nationwide because availability is concentrated in major urban and referral centres.

Genetic tests

There is no evidence that APOE testing or familial Alzheimer genetic testing is routinely incorporated into dementia diagnosis in Angola. Testing for APP, PSEN1 or PSEN2 mutations would therefore be exceptional and would most likely occur through research, private specialist arrangements or external referral. Routine genetic testing should not currently be considered part of Angola’s standard dementia pathway.

Biomarker tests

Rarely used

There is no evidence that CSF amyloid-β/tau testing, plasma phosphorylated-tau assays, amyloid PET or tau PET are routinely used in clinical dementia diagnosis in Angola. The existence of nuclear medicine infrastructure at tertiary hospitals shows broader technical capacity, but it does not demonstrate routine amyloid PET availability. The Ministry of Health’s current neuroscience programme is focused primarily on strengthening broader neurology and neurophysiology capacity, including care for Alzheimer’s disease. Advanced molecular dementia diagnostics therefore remain very limited and non-routine.

Cognitive Tests

Available

There is no evidence of a nationally mandated dementia cognitive screening instrument. Neurologists, psychiatrists and trained physicians can use conventional tools such as the MMSE, MoCA or similar bedside cognitive assessments, but no evidence was found of universal standardized use across the national public system. Formal neuropsychological assessment is likely to be concentrated in larger hospitals and specialist centres. Angola is expanding specialist medical training. The 2025 medical internship framework formally includes specialties such as Neurology, Geriatrics and Psychiatry, which may gradually strengthen the country’s capacity to assess cognitive disorders.

Imaging Tests

Used in specific cases

CT and MRI are available in Angola, particularly at tertiary hospitals and private diagnostic centres. The Cardeal Dom Alexandre do Nascimento hospital includes both an Imaging Service and a Nuclear Medicine Service within its formal structure. The same hospital has undergone major modernization and is equipped for high-complexity neurological and neurosurgical care, serving referred patients from several provinces. This means structural neuroimaging needed for dementia differential diagnosis is technically available. However, CT and MRI should not be described as universally or easily accessible nationwide because availability is concentrated in major urban and referral centres.

Genetic Tests

There is no evidence that APOE testing or familial Alzheimer genetic testing is routinely incorporated into dementia diagnosis in Angola. Testing for APP, PSEN1 or PSEN2 mutations would therefore be exceptional and would most likely occur through research, private specialist arrangements or external referral. Routine genetic testing should not currently be considered part of Angola’s standard dementia pathway.

Biomarker Tests

Rarely used

There is no evidence that CSF amyloid-β/tau testing, plasma phosphorylated-tau assays, amyloid PET or tau PET are routinely used in clinical dementia diagnosis in Angola. The existence of nuclear medicine infrastructure at tertiary hospitals shows broader technical capacity, but it does not demonstrate routine amyloid PET availability. The Ministry of Health’s current neuroscience programme is focused primarily on strengthening broader neurology and neurophysiology capacity, including care for Alzheimer’s disease. Advanced molecular dementia diagnostics therefore remain very limited and non-routine.

Treatment & Care

Angola’s dementia care system remains generalist, limited, and heavily reliant on families. There is no identified nationwide network of memory clinics or dedicated dementia centres; assessment and management are instead integrated into primary care, neurology, psychiatry, and internal medicine. Major referral facilities such as the Complexo Hospitalar Cardeal Dom Alexandre do Nascimento provide broader specialist capacity, while Alzheimer’s dementia is also recorded within mental-health services. However, low reported case numbers relative to expected prevalence may indicate substantial underdiagnosis or under-recording. Formal long-term and caregiver support is similarly non-specialised. MASFAMU oversees community and residential services for older people, including 18 homes across 11 provinces accommodating around 852 residents, alongside programmes such as Idoso no Lar and Idoso na Comunidade. AASTI provides additional social and psychological assistance, but there is no identified statutory dementia-specific long-term-care entitlement or comprehensive system of caregiver allowances, respite, counselling, or specialised education. Consequently, families remain responsible for much of the practical and financial burden of dementia care, including supervision, transport, household assistance, and institutional costs.

Specialized facilities and services

Angola has limited specialised dementia infrastructure, with no identified nationwide network of memory clinics or dedicated dementia centres. Assessment and management are integrated into primary care, neurology, psychiatry, and internal medicine, while complex cases can be referred to major hospitals such as the Complexo Hospitalar Cardeal Dom Alexandre do Nascimento in Luanda. Its services include neurology, neurosurgery, clinical psychology, imaging, nuclear medicine, and advanced laboratory diagnostics, with recent modernisation expanding specialist capacity. Although Alzheimer’s dementia is recorded within mental-health services, reported case numbers appear low relative to expected prevalence, suggesting that underdiagnosis or under-recording may be significant. Long-term care is also generalist: MASFAMU oversees residential services for older people, including 18 homes across 11 provinces accommodating approximately 852 residents. These facilities are not dementia-specific, leaving people with dementia reliant on broader medical, psychiatric, and social-care provision.

Angola does not appear to have a nationwide network of dedicated memory clinics or dementia centres, with dementia assessment and management instead incorporated into general neurology, psychiatry, internal medicine and primary healthcare services. More complex neurological assessment is available at major referral hospitals, including the Complexo Hospitalar Cardeal Dom Alexandre do Nascimento in Luanda, whose services include neurology, neurosurgery, internal medicine, clinical psychology, diagnostic imaging, nuclear medicine and advanced laboratory diagnostics. Recent investment and modernization have expanded the hospital’s capacity to manage complex neurological and other specialist conditions.

Dementia may also be managed through psychiatric and mental-health services, particularly when behavioural or psychological symptoms are present. Notably, official Angolan health statistics include “Dementia of Alzheimer’s Disease” among conditions recorded by mental-health services, although the relatively small number of reported cases compared with expected population prevalence suggests that many cases may remain undiagnosed or unrecorded.

Long-term social care for people with dementia is largely embedded within Angola’s broader services for older and vulnerable people rather than provided through dementia-specific facilities. The Ministry of Social Action, Family and Women’s Promotion (MASFAMU) oversees social-protection programmes for older people, including residential provision. Government reporting has identified 18 residential homes for older people across 11 provinces, accommodating approximately 852 residents at the time of reporting. These institutions are not specifically designed as dementia-care facilities, but they form part of the limited formal long-term-care infrastructure potentially available to older people experiencing cognitive and functional impairment. Consequently, Angola’s dementia-care capacity remains largely integrated into general medical, psychiatric and social-care structures rather than organised around specialised dementia services.

Approved medication

*Namzaric = combination of Donepezil and Memantine

Treatment cost

Angolan families face significant long-term dementia-care costs despite subsidised healthcare and general social assistance for vulnerable older people. Without a comprehensive dementia-specific long-term-care entitlement, households remain responsible for supervision, transport, household support, and potentially institutional care.

Public-sector healthcare provides subsidized medical care, but WHO identifies high out-of-pocket expenditure and inadequate financial protection as important continuing problems.1 Dementia creates particularly high household costs because treatment extends beyond medical consultations and medicines to include supervision, transport, household assistance and potentially institutional care Government programmes do provide some support to vulnerable older people MASFAMU reports programmes providing food support, housing assistance, social assistance and community-based support to older people. However, Angola has no comprehensive statutory dementia-specific long-term-care entitlement comparable with the long-term-care insurance systems found in some European countries Families therefore remain responsible for much of the direct and indirect cost of long-term dementia care.

Caregiver support

Angola’s dementia caregiving model is largely informal and family-based, with limited dedicated support for carers. No nationwide dementia-specific system or universal entitlement to caregiver allowances, respite, counselling, or specialised education has been identified. MASFAMU provides broader assistance to older people through programmes such as Idoso no Lar and Idoso na Comunidade, including residential, community, and social support. Organisations such as AASTI supplement these services with social and psychological assistance, but are not dementia-focused. With a limited network of Alzheimer’s or dementia-specific organisations, families have restricted access to specialised caregiver training, peer support, counselling, and respite, leaving dementia care primarily within informal family and general older-person support structures.

Family members appear to provide the majority of day-to-day dementia care in Angola, within a social-care model that places considerable emphasis on supporting older people within their families and communities. No nationwide dementia-specific caregiver support system or universal entitlement to regular respite care, dementia counselling or dedicated caregiver allowances was identified. Government support is instead delivered through broader older-person and social-protection programmes administered by the Ministry of Social Action, Family and Women’s Promotion (MASFAMU). Initiatives such as “Idoso no Lar” and “Idoso na Comunidade” aim to strengthen protection and assistance for older people in residential and community settings, while vulnerable older adults may also receive food and other forms of social assistance.

Some additional support is provided through civil-society organisations. The Associação de Amizade e Solidariedade para com a Terceira Idade (AASTI) works more broadly with older people and provides social and psychological assistance, with its activities receiving support from MASFAMU. However, AASTI is not specifically focused on dementia or dementia caregivers.2 Overall, the absence of a well-developed national network of Alzheimer’s or dementia-specific organisations means that families have relatively limited access to specialized caregiver education, counselling, peer-support groups and respite services. Dementia caregiving therefore remains largely embedded within informal family care and Angola’s broader older-person social-support system, rather than being supported by a dedicated dementia-caregiver infrastructure.

Policy

Angola’s dementia policy remains underdeveloped and integrated into broader health, ageing, and social-protection frameworks, with no dedicated National Dementia Strategy, Alzheimer’s Action Plan, or dementia-specific legislation identified as of September 2026. The WHO Angola Country Cooperation Strategy 2023–2027 prioritises stronger primary care, integrated services, NCD management, workforce development, and health-system resilience, while the National Policy for Older Persons and MASFAMU programmes provide a broader basis for addressing ageing, dependency, and family support. However, these frameworks do not establish comprehensive dementia-specific standards for diagnosis, referral, treatment, caregiving, surveillance, awareness, or research. There are signs of emerging specialist capacity: in 2025, MINSA included Alzheimer’s disease in a neuroscience capacity-building initiative, while formal training encompasses Neurology, Geriatrics, and Psychiatry. These reforms may strengthen future dementia care, but persistent fragmentation between health and social care, geographical disparities, high out-of-pocket costs, limited surveillance, and reliance on family caregiving remain significant system-level gaps.

National dementia plan

Angola lacks a dedicated National Dementia Strategy, with dementia addressed indirectly through broader healthcare, NCD, ageing, and social-protection frameworks. Current policies prioritise stronger primary and integrated care and provide support for older and vulnerable people, creating a foundation for dementia-related services. However, they do not establish dementia-specific targets, standardised diagnostic and referral pathways, treatment access, caregiver support, workforce training, surveillance, awareness, or research. Dementia therefore remains without a comprehensive and coordinated national policy framework.

Angola does not appear to have a dedicated National Dementia Strategy or Alzheimer Action Plan, with dementia instead addressed indirectly through broader policies covering primary healthcare, neurological and mental-health care, non-communicable diseases (NCDs), ageing, social protection and general health-system strengthening. The WHO Angola Country Cooperation Strategy 2023–2027 prioritizes strengthening primary healthcare, improving integrated and people-centred services across the life course, addressing NCDs and improving the overall resilience and capacity of the health system. These priorities are relevant to dementia prevention, diagnosis and management, particularly through improved primary and specialist care, but the strategy does not establish a dementia-specific national framework, targets or standardized care pathway.

Dementia is also indirectly covered by Angola’s broader policies concerning older people and social protection. The country has established a National Policy for Older Persons, while the Ministry of Social Action, Family and Women’s Promotion (MASFAMU) has reported work on a National Strategy for the Implementation of the Older Person Policy, alongside programmes intended to strengthen protection, social inclusion and assistance for older and vulnerable people. These measures provide a relevant policy foundation for dementia because they address ageing, dependency, family and community support and the social needs of older adults. However, they do not substitute for a comprehensive dementia strategy establishing specific objectives for early detection and diagnosis, clinical standards and referral pathways, access to treatment, caregiver support, professional training, epidemiological surveillance, public awareness and dementia research.

Upcoming plans

Angola is strengthening its broader health system rather than developing a dedicated dementia framework, with reforms targeting primary care, workforce development, health information, and medicine access. Dementia-relevant capacity is nevertheless expanding through neuroscience initiatives that explicitly include Alzheimer’s disease and postgraduate training in Neurology, Geriatrics, and Psychiatry. These developments could improve detection, referral, and specialist care, although no standalone national dementia strategy had been identified by September 2026.

Current reform in Angola remains focused primarily on broader health-system modernization and progress toward Universal Health Coverage (UHC) rather than the development of a dedicated dementia strategy. Key priorities include strengthening primary healthcare, expanding and training the health workforce, improving health-information systems, and reinforcing pharmaceutical regulation and access to essential medicines. These reforms could indirectly improve dementia care by increasing opportunities for earlier detection, referral and continuity of care, but they are designed to strengthen the health system as a whole rather than establish dementia-specific services or standards.

At the same time, there are indications of increasing investment in neurological and specialist capacity relevant to dementia. In 2025, the Ministry of Health (MINSA) explicitly included Alzheimer’s disease among the neurological conditions addressed through a technical neuroscience capacity-building initiative, alongside other neurological disorders.2Angola is also formalizing postgraduate specialist training through its medical internship framework, including Neurology, Geriatrics and Psychiatry, all of which are important disciplines for dementia diagnosis and management.3These developments should gradually strengthen the professional capacity available for cognitive assessment and dementia care; however, no announced standalone national dementia strategy or Alzheimer action plan was identified as of September 2026.

Policy gaps

Legal barriers

Angola’s dementia care remains fragmented between general healthcare, social-protection services, and family support, without dedicated legal provisions. High household costs and geographic disparities restrict equitable access, while the apparent lack of comprehensive dementia surveillance complicates needs assessment, service monitoring, and resource planning.

Dementia care in Angola is governed indirectly through general health, ageing, disability and social-protection frameworks rather than through dedicated dementia legislation. A key structural challenge is the fragmentation between medical and social care: diagnosis and clinical treatment are provided through the health system, while long-term supervision, residential care and assistance for dependent older people remain largely within family and social-protection structures. Financial barriers further limit access, particularly where medicines, diagnostic tests or specialist services require direct household expenditure. WHO has identified health-sector underfunding and high out-of-pocket expenditure as important obstacles to equitable access and progress toward Universal Health Coverage in Angola. These problems are compounded by geographical inequalities in access to specialist and higher-level services. The apparent absence of a comprehensive national dementia registry or surveillance system also makes it more difficult to establish the scale of need, monitor service utilisation and plan dementia-specific resources.

Cultural barriers

Cultural perceptions of ageing, mental illness, and behavioural change may affect dementia recognition and help-seeking in Angola. Stigma, discrimination, and beliefs surrounding spiritual disturbance can increase vulnerability, while reliance on family and community care may leave caregiver burden, psychological stress, and respite needs less visible.

Dementia recognition and help-seeking may also be affected by broader social and cultural attitudes toward ageing, mental health and behavioural change. Cognitive decline, personality changes or unusual behaviour may not always be recognised as symptoms requiring medical assessment and can potentially be interpreted through understandings of normal ageing, mental illness or spiritual disturbance. Importantly, the Angolan government itself has highlighted wider problems affecting older people, including neglect, discrimination, violence and accusations of witchcraft, while calling for greater protection and promotion of healthy and active ageing. Such attitudes are particularly relevant to dementia because progressive cognitive and behavioural symptoms can increase vulnerability to stigma, misunderstanding and social exclusion. Strong traditions of family and community support can provide an important source of care, but heavy reliance on informal caregiving can also leave caregiver burden, psychological stress and respite needs less visible to formal health and social-service institutions.

Research

Angola is strengthening the health-system foundations relevant to dementia, particularly through neuroscience capacity-building, specialist medical training, tertiary infrastructure, and health-information reform. MINSA’s 2025 initiative explicitly includes Alzheimer’s disease, while training in Neurology, Geriatrics, Psychiatry, imaging, and laboratory medicine, together with multidisciplinary capacity at the Complexo Hospitalar Cardeal Dom Alexandre do Nascimento, could improve future diagnosis and management. WHO-supported data reforms and INE’s healthy-ageing work may also strengthen planning for an ageing population. However, research and surveillance capacity remain limited. No comprehensive national dementia registry or substantial domestic Alzheimer’s therapeutic clinical-trial programme has been identified, and there is no evidence of routine participation by Angolan centres in pivotal anti-amyloid trials. National planning therefore continues to rely on hospital and broader mental-health data, alongside international epidemiological modelling. These developments provide a foundation for future progress, but capacity remains concentrated in specialist settings and requires sustained investment.

Selected academic institutions

Universidade Agostinho Neto

Clinical trials and registries

No substantial domestic Alzheimer therapeutic clinical-trial programme was identified. No evidence was found of Angolan centres routinely participating in pivotal anti-amyloid trials. Angola also lacks a comprehensive national dementia registry. This means national planning relies heavily on hospital data, broader mental-health statistics and international epidemiological modelling.

Selected innovative methods

Angola is developing several system-level foundations for stronger dementia care, although these initiatives are not dementia-specific. MINSA’s 2025 neuroscience capacity-building programme explicitly includes Alzheimer’s disease and supports professional training and clinical development through international cooperation. Specialist medical training is also being expanded in Neurology, Geriatrics, Psychiatry, imaging, and laboratory medicine, while the modernised Complexo Hospitalar Cardeal Dom Alexandre do Nascimento provides multidisciplinary neurological and diagnostic capacity, including imaging, nuclear medicine, psychology, and laboratory services. Further potential lies in health-information and healthy-ageing reforms. WHO-supported improvements to national health data could strengthen planning and monitoring in a context where dementia remains under-recorded, although no dedicated dementia registry has been identified. INE’s work on the ageing population also provides evidence on older people’s demographic and socioeconomic circumstances. Together, these developments could support future improvements in dementia diagnosis, specialist care, surveillance, prevention, and long-term support, but capacity remains concentrated in specialist settings and requires sustained workforce and health-system investment.

National Neuroscience Capacity-Building Initiative: Angola’s Ministry of Health (MINSA) is strengthening national technical and professional capacity in the neurosciences, with Alzheimer’s disease, Parkinson’s disease, epilepsy and stroke explicitly identified among the neurological conditions of interest. In 2025, this included cooperation with Professor Fernando Cendes of the University of Campinas (UNICAMP), focusing on knowledge exchange, professional training and development of diagnostic and clinical capacity. Although this is not a dementia-specific programme, the explicit inclusion of Alzheimer’s disease represents an important step toward improving national expertise in dementia diagnosis and management.

Expansion of Specialist Medical Training: Angola is simultaneously expanding and formalizing its specialist medical workforce through the national medical internship framework. The framework covers disciplines directly relevant to dementia care, including Neurology, Geriatrics and Psychiatry, alongside diagnostic and supporting specialties such as radiology/imaging and laboratory medicine. Increasing the number and geographical distribution of trained specialists could gradually improve access to cognitive assessment, differential diagnosis, management of behavioural and psychological symptoms and follow-up of people with dementia, although development of this workforce will require sustained investment over time.

Modernized Tertiary Neurological Infrastructure: Investment in major referral hospitals is also increasing Angola’s capacity to investigate and manage complex neurological conditions. The Complexo Hospitalar Cardeal Dom Alexandre do Nascimento brings together neurology with neurosurgery, diagnostic imaging, nuclear medicine, clinical psychology, internal medicine and advanced laboratory services. This multidisciplinary infrastructure is relevant to dementia because complex cognitive disorders may require neurological examination, structural imaging, laboratory investigation and assessment of psychiatric or psychological symptoms. However, such advanced capacity remains part of tertiary specialist care rather than a nationwide network of dedicated memory clinics.

Health Information System Modernization: Angola is working with WHO to strengthen health-information systems, data collection and national capacity to use health information for planning and decision-making. Better routine health data could be particularly important for dementia, where limited epidemiological information and under-recording make it difficult to estimate service needs accurately. Stronger information systems could eventually support better monitoring of neurological and age-related conditions, allocation of resources and development of evidence-based dementia policies, although a dedicated national dementia registry has not been identified.

Healthy Ageing Policy Development: Population ageing is receiving greater attention within Angola’s demographic and social-policy agenda. The National Statistics Institute (INE) has produced thematic analysis of the country’s older population in the context of the United Nations Decade of Healthy Ageing (2021–2030), helping to build a stronger evidence base on the demographic and socioeconomic circumstances of older Angolans.5While this work is not dementia-specific, greater policy attention to healthy ageing, functional ability, dependency and the needs of older people provides an important foundation for the future integration of dementia prevention, diagnosis, long-term care and caregiver support into national ageing policy.

Support

Organizations are listed for informational purposes based on publicly available sources. Inclusion does not necessarily indicate affiliation with or endorsement by Alzheimer’s Disease International (ADI).

Angola is strengthening dementia-relevant capacity through broader neuroscience, ageing, social-protection, awareness, and professional-training initiatives, although these remain fragmented rather than forming a coordinated national system. Alzheimer’s disease is gaining recognition within neurological and professional education programmes, while wider ageing initiatives support vulnerable older people. Public communication remains limited, with no dedicated dementia media outlet and information mainly provided through government institutions, WHO Angola, and general media.

Selected national associations, patient family associations, NGOs:

Associacao de Amizade e Solidariedade para com a Terceira Idade - AASTI

Selected initiatives

Angola is developing dementia-relevant support through broader neuroscience, ageing, social-protection, awareness, and professional-training initiatives. MINSA’s neuroscience programme explicitly includes Alzheimer’s disease and promotes specialist capacity-building and knowledge exchange. The National Policy for Older Persons and programmes such as Idoso no Lar and Idoso na Comunidade provide wider protection and community support relevant to people with cognitive and functional decline. Healthy-ageing campaigns addressing dignity, discrimination, neglect, violence, and witchcraft accusations may provide foundations for future dementia awareness and anti-stigma efforts. Professional education is also beginning to address dementia more directly, including diagnosis and treatment in later life. However, these measures remain dispersed across broader health and social programmes rather than forming a coordinated, nationwide dementia-specific system.

National Neuroscience Strengthening Programme
The Ministry of Health (MINSA) has begun strengthening Angola’s technical and professional capacity in neurosciences, explicitly identifying Alzheimer’s disease, Parkinson’s disease, epilepsy and stroke among the neurological conditions targeted. The initiative includes international knowledge exchange and specialist capacity building and could contribute to improving neurological diagnosis and management of dementia, although it is not a dedicated national dementia programme.
National Policy for Older Persons
Angola’s National Policy for Older Persons provides a broader framework for protecting the rights, dignity and social inclusion of older people. Its relevance to dementia lies particularly in addressing vulnerability, dependency, family and community support, and access to social protection among an ageing population. While the policy is not dementia-specific, it provides an institutional foundation through which the social-care needs of people with cognitive impairment can potentially be addressed.
Idoso no Lar / Idoso na Comunidade
These government social-protection initiatives are intended to provide assistance to vulnerable older people in residential and community settings, complementing Angola’s wider policies on ageing and social protection. Although neither programme is specifically designed for dementia, community-based support is particularly relevant to people experiencing cognitive and functional decline who remain dependent on relatives and informal caregivers. The programmes therefore represent part of the broader social infrastructure within which dementia-related needs are currently addressed.
Healthy and Active Ageing Awareness Activities. MASFAMU has promoted public awareness around healthy and active ageing, dignity and respect for older people, while drawing attention to problems such as neglect, discrimination, violence and accusations of witchcraft affecting some older Angolans. These activities are relevant to dementia because cognitive and behavioural changes can increase vulnerability to stigma, mistreatment and social exclusion. Greater public understanding of ageing may therefore provide a foundation for future dementia-awareness and anti-stigma initiatives, even though current campaigns are not specifically focused on cognitive impairment.

Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /home/bcdafabe/public_html/wp-content/themes/bricks-child/functions.php on line 753
Professional Dementia Training
Professional education is beginning to include more explicit attention to dementia and mental health in later life. Angola’s major Psychiatry and Mental Health Congress in 2026 included a dedicated workshop on Mental Health in Older People, covering topics such as the diagnosis and treatment of dementia, depression among older adults and appropriate use of medication in old age. This represents an important emerging opportunity to improve dementia knowledge among health professionals and strengthen recognition and management of cognitive disorders. However, it remains a professional education and capacity-building initiative rather than a standardized nationwide dementia-training or clinical programme.

Dedicated media outlets

Angola does not appear to have a dedicated Alzheimer or dementia media outlet. The most authoritative dementia-related information is generally published through the Ministry of Health, MASFAMU, WHO Angola and the National Statistics Institute. General media including Jornal de Angola, ANGOP and O País periodically cover ageing, neurological disease and social-protection issues, but dementia remains a comparatively low-profile health topic.

Understanding the terms

This section explains key terms used throughout the text to help readers better understand the exploration concepts.
Open Term Glossary
SHARE YOUR INSIGHTS

Do you have insights about Alzheimer’s Disease in your country?

Please share it with us and help us make AD Atlas better!
Can we contact you for feedback?
Contents

Understanding the Terms

Terms used throughout this website are explained below.
A

Amyloid-Targeting Therapies (ATT): A class of disease-modifying treatments, primarily monoclonal antibodies, designed to identify and remove amyloid-beta plaques from the brain to slow cognitive and functional decline in early-stage Alzheimer’s. Examples include Lecanemab and Donanemab.

Aphasia: A language disorder that affects a person’s ability to communicate, often seen early in Frontotemporal Dementia.

APOE ε4 Allele: A genetic variant of the Apolipoprotein E gene that is a major risk factor for late-onset Alzheimer’s disease; while not a causative gene, its presence increases the likelihood of developing the condition.

Acetylcholinesterase Inhibitors: A class of medications, including Donepezil, Rivastigmine, and Galantamine, used to treat cognitive symptoms by increasing levels of chemical messengers in the brain.

Advance Directives (DAT): Legal documents, such as Disposizioni Anticipate di Trattamento in Italy, that allow individuals to specify their future medical treatment and care preferences while they still have the capacity to do so.

Alzheimer’s Disease (AD): The most common cause of dementia, characterized by a progressive neurodegenerative decline caused by the accumulation of amyloid plaques and tau tangles in the brain.

Amyloid-beta Plaques: Protein fragments that build up in the spaces between nerve cells, disrupting communication and triggering immune responses.

Amyloid PET Scan: A specialized nuclear imaging test that uses radioactive tracers to visualize and measure the density of amyloid-beta plaques in the living brain.

Atrophy: The wasting away or shrinking of brain tissue, often measured via MRI to support a clinical diagnosis of dementia or Alzheimer’s.

B

Biomarkers: Measurable biological indicators, such as proteins found in blood or cerebrospinal fluid, used to identify the underlying pathology of a disease.

Blood Biomarkers: Emerging, less-invasive diagnostic tests that measure specific proteins like p-tau or neurofilament levels in blood plasma to detect Alzheimer’s pathology.

C

CSF Analysis (Cerebrospinal Fluid): A diagnostic procedure involving a lumbar puncture to measure levels of tau and amyloid-beta proteins in the fluid surrounding the brain and spinal cord.

CT Scan (Computed Tomography): A diagnostic imaging test using X-rays to create detailed cross-sectional images of the brain; used primarily to rule out other causes of cognitive decline such as tumors or strokes.

Clock Drawing Test (CDT): A brief cognitive screening task where a patient is asked to ask to draw a clock face; it evaluates visuospatial and executive function.

Cognitive Screening: The process of using standardized tests to objectively measure an individual’s mental functions, such as memory, orientation, and attention.

Community-based Care: Healthcare and support services provided within the local community, such as daycare centers, home-based nursing, and local support groups, rather than in institutional settings.

Cube Copying Test: A visuospatial assessment task used during neuropsychological evaluations to test a patient’s ability to replicate geometric shapes.

D

Dementia: An umbrella term for a range of neurological conditions characterized by a decline in memory, language, and thinking skills severe enough to interfere with daily life.

Dementia-friendly Society: A community or national environment where citizens and businesses are trained to understand, respect, and support the needs of people living with dementia.

Disease-modifying Therapies (DMTs): A new class of treatments, such as monoclonal antibodies (e.g., Lecanemab), designed to target the underlying biological causes of Alzheimer’s rather than just managing symptoms.

E

Early-Onset Alzheimer’s: A form of the disease that affects people younger than age 65, often linked to the familial genes.

Executive Function: Higher-level mental skills including planning, focusing, and multitasking; these are often what the Clock Drawing Test evaluates.

F

FDG-PET: A type of PET scan that measures glucose metabolism in the brain to identify patterns characteristic of different dementia subtypes.

Familial Alzheimer’s Disease: A rare, genetic form of the disease linked to mutations in specific genes (APP, PSEN1, PSEN2) that typically presents with early-onset symptoms.

Frontotemporal Dementia (FTD): A type of dementia caused by progressive nerve cell loss in the frontal or temporal lobes, leading to significant changes in behavior, personality, and language.

G

General Practitioner (GP): A primary care physician who acts as the first point of contact and gatekeeper for dementia diagnosis, providing initial assessments and referrals to specialists.

Genotyping: The analysis of an individual’s DNA to identify specific genetic variations associated with dementia risk or causation.

H

Hidden Cost: The indirect economic impacts of dementia, such as the loss of income for family members who must reduce working hours or leave their jobs to provide care.

I

Informal Care / Informal Caregiver: Unpaid care provided by family members, spouses, or friends, which represents the vast majority of long-term support for people living with dementia.

J

Japanese Cognitive Function Test (J-Cog): A specialized cognitive assessment tool used to evaluate mental and functional status in specific research or regional contexts.

L

Lewy Body Dementia (LBD): A type of progressive dementia that leads to a decline in thinking, reasoning, and independent function due to abnormal microscopic deposits that damage brain cells.

Long-Term Care Insurance (LTCI): A specialized branch of insurance, found in systems like Germany and Singapore, that provides financial subsidies for daily living assistance and nursing care.

M

Memory Clinic: A specialized, often multidisciplinary center focused on the expert diagnosis, management, and treatment of dementia and cognitive disorders.

Mild Cognitive Impairment (MCI): An intermediate stage between normal aging and dementia where memory or thinking problems are noticeable but don’t yet prevent daily functioning.

Mini-Mental State Examination (MMSE): A 30-point standardized questionnaire used to measure cognitive impairment by testing orientation, recall, and attention.

Montreal Cognitive Assessment (MoCA): A cognitive screening tool designed to be more sensitive than the MMSE, particularly for identifying Mild Cognitive Impairment.

MRI Scan (Magnetic Resonance Imaging): A non-invasive technology using magnetic fields to produce detailed images of brain structure; used to assess brain atrophy and rule out secondary causes.

N

National Dementia Plan: A formal government strategy outlining a coordinated response to manage dementia diagnosis, care, research, and awareness at a national level.

National Health Insurance (NHI): A government-funded or regulated healthcare system providing universal or subsidized medical services to citizens.

Neuroimaging: The use of advanced techniques, such as CT, MRI, and PET, to visualize the structure and function of the brain for diagnostic purposes.

Neuroinflammation: The brain’s immune response to damage or protein buildup; while initially protective, chronic inflammation can accelerate neurodegeneration.

O

Out-of-Pocket Costs: Direct payments made by patients or their families for medical services, tests, or care that are not covered by insurance or public subsidies.

P

Preclinical Alzheimer’s: The stage where brain changes (like amyloid buildup) are present but no outward symptoms are yet visible.

S

Synaptic Loss: The destruction of synapses (the gaps where neurons communicate), which is often the strongest correlate to cognitive decline.

T

Tau Tangles: Twisted fibers of a protein called tau that build up inside nerve cells, destroying the cell’s transport system.

V

Vascular Dementia: The second most common type of dementia, caused by conditions that block or reduce blood flow to the brain, like strokes.